2.02

8.60% 0.16

Pre-market: 2.04 0.02 +0.99%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $2.02, with a volume of 1.01M. It is up +8.60% in the last 24 hours and up +62.90% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.86

Open:

$1.85

24h Volume:

1.01M

Relative Volume:

1.44

Market Cap:

$53.70M

Revenue:

$50,000

Net Income/Loss:

$-41.60M

P/E Ratio:

-1.192

EPS:

-1.6946

Net Cash Flow:

$-20.20M

1W Performance:

+16.09%

1M Performance:

+62.90%

6M Performance:

+31.17%

1Y Performance:

-4.72%

1-Day Range:

$1.8207

$2.08

1-Week Range:

$1.6512

$2.08

52-Week Range:

$1.09

$3.244

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1092)

Industry

Biotechnology (614)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-08-06

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	2.02	49.45M	50,000	-41.60M	-20.20M	-1.6946
VRTX Vertex Pharmaceuticals Inc	476.31	121.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.12	69.52B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	859.43	54.49B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	184.97	39.11B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	281.26	38.46B	4.29B	577.22M	641.34M	4.2086

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Jul 13, 2026

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC - The Manila Times

Jul 09, 2026

INmune Bio Reports Concordant MRI Biomarker Changes Supporting Early XPro Treatment Activity in Phase 2 Alzheimer’s Study - Quiver Quantitative

Jul 09, 2026

INmune Bio reports imaging data from Alzheimer’s drug trial By Investing.com - Investing.com Canada

Jul 09, 2026

INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes - Stock Titan

Jul 09, 2026

Jul 07, 2026

Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com South Africa

Jul 07, 2026

Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan

Jul 07, 2026

INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan

Jul 07, 2026

Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan

Jul 07, 2026

Jul 06, 2026